COMMUNIQUÉS West-GlobeNewswire

Cabaletta Bio Announces 2026 Strategic Priorities
12/01/2026
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment cleared to [...]
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
12/01/2026
New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026 NDA submission for GIST on track for April 2026; bezuclastinib has the potential to be the first new [...]
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones
12/01/2026
Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015 during [...]
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance
12/01/2026
Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5% Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11% Fiscal 2026 [...]
New Data Underscoring Ability of Leapfrog Bio’s OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal
12/01/2026
-- Study highlights importance of cancer driver biology in translating results from lab to patients -- -- Findings validate proprietary OncoSLX Platform™, a pharmacogenetic approach that captures the full spectrum of [...]
Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds
12/01/2026
DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc . ® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that it has entered into definitive agreements for the [...]
Geron Corporation Provides 2026 Financial Guidance
12/01/2026
2026 RYTELO ® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and streamlined [...]
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026
12/01/2026
– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart – – Recruitment ongoing for Phase 1b study of intravenously-administered rademikibart designed to [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/01/2026
CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
Canadian Red Cross opens appeal to expand support for the Pimicikamak Cree Nation Crisis
09/01/2026
WINNIPEG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Canadian Red Cross has launched the 2026 Pimicikamak Cree Nation Crisis Appeal to provide support for those impacted by the power outage in Pimicikamak Cree Nation, [...]
La Croix-Rouge canadienne sollicite des dons afin de bonifier le soutien offert aux personnes touchées par la crise dans la Nation crie de Pimicikamak
09/01/2026
WINNIPEG, 09 janv. 2026 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne a mis sur pied le Fonds de secours : Crise de 2026 dans la Nation crie de Pimicikamak pour venir en aide aux personnes touchées par la panne de [...]
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
09/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/01/2026
BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Gastro Center of Maryland Expands Columbia Team with New Board-Certified Gastroenterologists
09/01/2026
COLUMBIA, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Gastro Center of Maryland is pleased to announce the addition of new board-certified gastroenterologists to its Columbia location at 7120 Minstrel Way, Suite 100. This [...]
China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering
09/01/2026
TAIZHOU, China, Jan. 09, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive agreement with a single investor for the purchase [...]
Most Popular SARMS for Bulking, Muscle Building and Strength 2026: Latest SARM Stacks for Muscle Growth & Bodybuilding - CrazyBulk
09/01/2026
Best SARM for muscle growth and strength for 2026 from leading supplement company CrazyBulk - which SARMS stack is best for bulking cycles and faster recovery" New York City,, Jan. 09, 2026 (GLOBE NEWSWIRE) -- "SARMs [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/01/2026
BRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics granted [...]
Virbac : Declaration of the number of shares and voting rights 12/2025
09/01/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 12/2025
09/01/2026
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]

Pages